当前位置: X-MOL 学术CNS Spectr. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Is quetiapine effective for obsessive and compulsive symptoms in patients with bipolar disorder? A randomized, double-blind, placebo-controlled clinical trial
CNS Spectrums ( IF 3.3 ) Pub Date : 2021-05-24 , DOI: 10.1017/s1092852921000572
Ali Sahraian 1 , Bahareh Ghahremanpouri 1 , Arash Mowla 2
Affiliation  

Background

The aim of this study is to examine the effects of quetiapine as an adjuvant treatment for obsessive–compulsive (OC) symptoms in patients with bipolar disorder (BD) type I.

Methods

In this 8-week double-blind placebo-controlled randomized clinical trial, 47 patients with BD in euthymic phase that had OC symptoms were randomly allocated to receive either quetiapine or placebo plus their routine medications (lithium + clonazepam). Yale–Brown Obsessive–Compulsive Scale (YBOCS) was used to assess the outcomes. Adverse effects were also recorded.

Results

Of 47 BD patients with OC symptoms that were randomly allocated in two groups of quetiapine (n = 24) and placebo group (n = 23), 40 patients (20 in quetiapine group and 20 in placebo group) completed the trial. Throughout the trial, the mean score of YBOCS in the quetiapine group dropped from 24.37 ± 1.51 to 15.26 ± 1.16 (P < .001) and in the placebo group decreased from 24.21 ± 1.33 to 23.94 ± 1.66 (P = 1.97). At the end of the study, 12 (60%) patients in the quetiapine group and 1 (5%) patient in the placebo group had more than 34% decline in YBOCS score (P < .001). No serious adverse effects were reported in two groups.

Conclusions

Our double-blind placebo-controlled clinical trial showed that quetiapine may be an effective adjuvant agent for reducing OC symptoms in BD patients.



中文翻译:

喹硫平对双相情感障碍患者的强迫症状有效吗?一项随机、双盲、安慰剂对照的临床试验

背景

本研究的目的是检查喹硫平作为 I 型双相情感障碍 (BD) 患者强迫症 (OC) 症状辅助治疗的效果。

方法

在这项为期 8 周的双盲安慰剂对照随机临床试验中,47 名处于情绪正常期且有 OC 症状的 BD 患者被随机分配接受喹硫平或安慰剂加他们的常规药物(锂 + 氯硝西泮)。耶鲁-布朗强迫症量表 (YBOCS) 用于评估结果。不良反应也被记录下来。

结果

在随机分配到喹硫平组(n = 24)和安慰剂组(n = 23)两组的 47 名有 OC 症状的 BD 患者中,40 名患者(喹硫平组 20 名,安慰剂组 20 名)完成了试验。在整个试验过程中,喹硫平组的 YBOCS 平均分从 24.37 ± 1.51 下降到 15.26 ± 1.16 ( P  < .001),安慰剂组从 24.21 ± 1.33 下降到 23.94 ± 1.66 ( P  = 1.97)。研究结束时,喹硫平组 12 名 (60%) 患者和安慰剂组 1 名 (5%) 患者的 YBOCS 评分下降超过 34% ( P  < .001)。两组均未报告严重不良反应。

结论

我们的双盲安慰剂对照临床试验表明,喹硫平可能是减轻 BD 患者 OC 症状的有效辅助药物。

更新日期:2021-05-24
down
wechat
bug